Celldex Therapeutics (CLDX) Income from Continuing Operations (2010 - 2026)
Celldex Therapeutics (CLDX) recorded quarterly Income from Continuing Operations of 78685000.0 in Q1 2026, up 3.24% quarter-over-quarter from 81317000.0 in Q4 2025, and down 46.27% on a YoY basis from 146432983.71 in Q1 2025.
Celldex Therapeutics (CLDX) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Celldex Therapeutics' Income from Continuing Operations history runs 17 years deep, the most recent figure standing at 78685000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 46.27% year-over-year to 78685000.0; the TTM figure through Mar 2026 stood at 283646000.0 (down 58.59% YoY), while the FY2025 annual figure was 258757000.0, down 63.91% from the prior year.
- Income from Continuing Operations was 78685000.0 for Q1 2026 at Celldex Therapeutics, up from 81317000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 23050000.0 in Q1 2022 to a low of 81317000.0 in Q4 2025.
- Historically, Income from Continuing Operations has averaged 44062294.12 across 5 years, with a median of 38260000.0 in 2023.
- The sharpest annual moves came in 2022 and 2023: Income from Continuing Operations slumped 169.23% in 2022, then advanced 15.28% in 2023.
- A 5-year view of Income from Continuing Operations shows it stood at 26487000.0 in 2022, then sank by 63.5% to 43306000.0 in 2023, then declined by 8.74% to 47092000.0 in 2024, then sank by 72.68% to 81317000.0 in 2025, then increased by 3.24% to 78685000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 78685000.0 (Q1 2026), 81317000.0 (Q4 2025), and 67044000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Celldex Therapeutics | 2.16 Bn | 2.16 Bn | -1.44 Mn | -78.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -78.69 Mn |
| Dec 31, 2025 | -81.32 Mn |
| Sep 30, 2025 | -67.04 Mn |
| Jun 30, 2025 | -56.60 Mn |
| Mar 31, 2025 | -53.80 Mn |
| Dec 31, 2024 | -47.09 Mn |
| Sep 30, 2024 | -42.12 Mn |
| Jun 30, 2024 | -35.84 Mn |
| Mar 31, 2024 | -32.81 Mn |
| Dec 31, 2023 | -43.31 Mn |
| Sep 30, 2023 | -38.26 Mn |
| Jun 30, 2023 | -30.50 Mn |
| Mar 31, 2023 | -29.36 Mn |
| Dec 31, 2022 | -26.49 Mn |
| Sep 30, 2022 | -26.78 Mn |
| Jun 30, 2022 | -36.00 Mn |
| Mar 31, 2022 | -23.05 Mn |
| Dec 31, 2021 | -20.15 Mn |
| Sep 30, 2021 | -20.45 Mn |
| Jun 30, 2021 | -13.37 Mn |